View Document Preview and Link Document Date: 2014-02-13 14:27:52 Open Document File Size: 310,97 KB Share Result on Facebook
City Paris / SYMPOSIUM™ LEXINGTON / San Diego / / Company Synageva BioPharma Corp. / / Country France / / / Event FDA Phase / / Facility Necker-Enfants Malades Hospital / PKU Clinic / University of Minnesota / Lysosomal Storage Disease Clinic / / IndustryTerm drug product / manufacturing platform / biopharmaceutical company developing therapeutic products / / MedicalCondition LAL Deficiency LAL Deficiency / rare diseases / central line infections / LAL Deficiency A / rare autosomal recessive lysosomal storage disease / lysosomal acid lipase deficiency / cirrhosis / Cholesteryl Ester Storage Disease / cholecystitis/cholelithiasis / MPS IIIB The mucopolysaccharidoses / tachycardia / diarrhea / LAL Deficiency / B syndrome / rapidly progressive disease / Mucopolysaccharidosis IIIB / accelerated atherosclerosis / disease / dyslipidemia / fever / Wolman disease / diseases / often fatal disease / PKU / aggressive liver disease / deficiency / fibrosis / / MedicalTreatment antibiotics / liver transplant / enzyme replacement therapy / biologic therapies / / Organization Necker-Enfants Malades Hospital / Department of Pediatrics and Experimental / University of Minnesota / Minneapolis / European Medicines Agency / U.S. Food and Drug Administration / Ministry of Health / Gene Therapy Center / / Person Chester B. Whitley / Vassili Valayannopoulos / MPS IIIB / Matthew Osborne / / / Position Professor / Director / animal model / / Product SBC-103 / / ProvinceOrState Minnesota / California / Massachusetts / / Technology alpha / antibodies / transplantation / Gene Therapy / / URL www.synageva.com / / SocialTag 
SYNAGEVA BIOPHARMA™ HIGHLIGHTS SEBELIPASE ALFA AND LAL DEFICIENCY DATA AT THE LYSOSOMAL DISEASE NETWORK (LDN) WORLD SYMPOSIUM™ LEXINGTON, Mass., February 13, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA),